Alt Telecom Public Company Limited

Issued on behalf of Avant Technologies Inc.

VANCOUVER, BC, Jan. 29, 2026 /PRNewswire/ -- USA News Group News Commentary – Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27 trillion by 2030^[1]. This transition is moving the entire healthcare sector toward regenerative medicine which is projected to reach $578.59 billion by 2033^[2]. We are witnessing a total structural reset that creates massive upside for bio-restorative platforms capable of a systemic re-rating. This emerging investment class includes Avant Technologies, Inc. (OTCQB: AVAI), MannKind (NASDAQ: MNKD), Altimmune (NASDAQ: ALT), Lineage Cell Therapeutics (NYSE-A: LCTX), and Arrowhead Pharmaceuticals (NASDAQ: ARWR).

The latest data shows cell therapy markets hitting $8.85 billion by 2026^[3] while AI-driven drug discovery platforms are accelerating to $24.51 billion^[4]. These figures confirm that institutions are now positioning for the convergence of cell-encapsulation technology and precision metabolic delivery. This structural shift is opening a massive window for platforms that can address the $65.2 billion metabolic syndrome opportunity with curative infrastructure rather than simple symptom management. For the smart money, these cell-based and gene-targeted therapies are officially the longevity alpha of the 2026 cycle.

Avant Technologies, Inc. (OTCQB: AVAI) made waves at the 15th European Pancreas and Islet Transplantation Association (EPITA) Symposium, where Dr. Eva Maria Lilli Brandtner is evaluating advanced cells for potential application in a diabetes therapy. The Austria-based event, which ran January 25-27, 2026, brought together global scientists and clinicians focused on biological therapies for diabetes. EPITA stands as one of the world's flagship associations for networking on islet transplantation and beta cell replacement, making Avant's participation particularly significant for the emerging biotechnology company.

Dr. Brandtner is assessing promising cells for inclusion with Avant's Cell-in-a-Box® technology, developed in partnership with SGAustria Pte. Ltd. This clinically proven microencapsulation platform solves a critical problem: when doctors transplant therapeutic cells into patients, the immune system typically destroys them within days or weeks. The traditional solution requires lifelong immunosuppressive drugs that carry serious risks, including infections, organ damage, and elevated cancer risk.

"While stem cell-derived beta cells undoubtedly represent a breakthrough in unlimited insulin sources, immune protection still remains a key challenge," Dr. Brandtner said. "Avant's Cell-in-a-Box® technology addresses this effectively, positioning us to contribute meaningfully to beta cell replacement therapies for type 1 and insulin-dependent type 2 diabetes patients worldwide."

The cell encapsulation technology creates a protective barrier around therapeutic cells while still allowing nutrients, oxygen, and therapeutic proteins to pass through freely. This approach eliminates the need for immunosuppressive drugs while preventing potential complications such as cell escape or tumor formation, making it a cornerstone for safe and scalable diabetes therapies.

Avant operates through two joint ventures targeting massive markets. Insulinova, Inc. partners with SGAustria to develop treatments for type 1 diabetes and insulin-dependent type 2 diabetes. The approach uses genetically modified cells that produce, regulate, and store insulin, essentially creating a bioartificial pancreas that restores natural glucose control. The diabetes market opportunity is substantial: 589 million people globally live with type 1 and insulin-dependent type 2 diabetes, projected to reach 853 million by 2050 according to the International Diabetes Federation.

The second venture, Klothonova, partners with Singapore-based Austrianova to develop therapies for age-related diseases and anti-aging therapies using cells that produce the Klotho protein. Research from the Mayo Clinic links declining Klotho levels to arterial stiffness, endothelial dysfunction, and vascular calcification.

Both platforms are backed by over 50 peer-reviewed publications representing decades of development. The addressable markets span Alzheimer's disease ($32.8 billion by 2033), cardiovascular disease (32% of global deaths), and kidney disease (850 million affected worldwide).

CONTINUED… Read this and more news for Avant Technologies Inc. at https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ and https://usanewsgroup.com/avai-profile/

MannKind Corporation (NASDAQ: MNKD) announced FDA approval of an updated Prescribing Information for Afrezza (insulin human) Inhalation Powder, revising recommendations for starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens including multiple daily injections or insulin pump therapy. The updated initial conversion table is based on clinical trials in adults showing significantly improved mealtime glycemic excursions with the revised dosing approach.

"We expect that this label update will help support healthcare providers by providing clearer starting dose guidance when transitioning patients to inhaled insulin from subcutaneous mealtime insulin—whether injections or insulin pumps," said Dr. Kevin Kaiserman, Senior Vice President, Therapeutic Area Head, Diabetes at MannKind. "We believe this refinement to the label helps support appropriate initiation of therapy while reinforcing Afrezza's established clinical profile."

The updated labeling was supported by modeling data and in vivo results from the Dose Optimization study and INHALE-3 trial demonstrating improved postprandial glucose outcomes following conversion to inhaled insulin using the now-approved conversion dose. Afrezza is the only ultra rapid-acting inhaled insulin approved by the FDA to improve glycemic control in adult patients with diabetes mellitus, administered at the beginning of meals using a small portable inhaler that delivers insulin via MannKind's proprietary Technosphere technology.

Altimmune (NASDAQ: ALT) received FDA Breakthrough Therapy Designation for pemvidutide for treatment of patients with metabolic dysfunction-associated steatohepatitis. Breakthrough Therapy Designation is intended to expedite development and review of medicines treating serious conditions that have shown preliminary clinical evidence indicating potential for substantial improvement over available therapies.

"The FDA's Breakthrough Therapy Designation for pemvidutide in MASH reinforces the promise of its clinical profile and potential to address significant unmet needs in this serious, progressive liver disease," said Jerry Durso, President and CEO of Altimmune. "As I step into the CEO role, this designation represents an important validation for pemvidutide."

Altimmune completed a productive end-of-phase 2 meeting with the FDA resulting in alignment on parameters for a registrational Phase 3 trial of pemvidutide in MASH patients with moderate to advanced liver fibrosis. The company plans to initiate a Phase 3 trial evaluating multiple pemvidutide doses over a 52-week treatment period incorporating biopsy-based endpoints to support a potential accelerated approval.

Lineage Cell Therapeutics (NYSE-A: LCTX) has received delivery of a novel gene-edited hypoimmune cell line from Factor Bioscience under their strategic collaboration. The proprietary induced pluripotent stem cell line contains hypoimmunity edits designed to support non-immune privileged indications and includes an additional disease-specific edit with potential to differentiate this cell line from competing therapies.

"Our partnership with Factor supports our plan to create novel and superior product candidates by combining our manufacturing and process development capabilities with cutting-edge cell engineering and editing technologies," stated Brian M. Culley, CEO of Lineage Cell Therapeutics. "This achievement under our collaboration with Factor supports our plan to broaden our cell therapy platform through the addition of new technologies and indications, as we await further updates from our lead cell therapy program, OpRegen, for dry age-related macular degeneration with geographic atrophy."

Lineage will evaluate the cell line for its ability to adapt to the company's proprietary AlloSCOPE manufacturing platform. The clinical-stage biotechnology company develops allogeneic cell therapies for serious medical conditions with a pipeline including OpRegen for retinal disease and OPC1 for spinal cord injuries.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the first clinical candidate designed to silence expression of two genes simultaneously in one molecule for treatment of atherosclerotic cardiovascular disease due to mixed hyperlipidemia. The investigational RNA interference therapeutic targets both proprotein convertase subtilisin kexin 9 and apolipoprotein C3 genes, representing an important step forward enabled by Arrowhead's proprietary Targeted RNAi Molecule platform.

"Arrowhead is at the forefront of innovation in the RNAi field, and we're proud of the versatile capabilities of our TRiM platform, now including the first-ever clinical candidate that can potentially silence expression of two genes in one RNAi molecule," said Chris Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. "ARO-DIMER-PA is designed to silence both the PCSK9 and APOC3 genes, which together have substantial clinical validation as important targets for reducing LDL-cholesterol, triglycerides, and total atherogenic lipoproteins."

In preclinical studies, ARO-DIMER-PA potently lowered serum PCSK9 and APOC3 and ameliorated high levels of non-HDL-cholesterol, LDL-cholesterol, and triglycerides in hyperlipidemic nonhuman primates. The initiation advances Arrowhead's growing cardiometabolic portfolio including commercial product REDEMPLO approved in the United States, Canada, and China for familial chylomicronemia syndrome, ongoing Phase 3 study of zodasiran in homozygous familial hypercholesterolemia, and Phase 1/2 studies of ARO-INHBE and ARO-ALK7 for obesity.

Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 

CONTACT:

USA NEWS GROUP

info@usanewsgroup.com

(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES CITED:

1. https://theweek.com/business/longevity-economy-booming-live-longer
2. https://www.globenewswire.com/news-release/2026/01/27/3226653/0/en/Regenerative-Medicine-Market-Review-2020-2024-and-Forecast-2025-2033-A-578-29-Bn-Opportunity-Says-Astute-Analytica.html
3. https://www.towardshealthcare.com/insights/cell-therapy-market-sizing
4. https://www.towardshealthcare.com/insights/artificial-intelligence-in-drug-discovery 

Logo - https://mma.prnewswire.com/media/2838876/5742703/USA_News_Group_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/longevity-biotech-stocks-surge-as-27-trillion-healthcare-shift-favors-cell-restoration-302674367.html

NEW YORK, Oct. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).

Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form-2/?id=170616&from=4

CLASS PERIOD: August 10, 2023 to June 25, 2025

ALLEGATIONS: According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. While defendants had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, defendants answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial.  Following this news, the price of Altimmune's common stock declined dramatically. From a closing market price of $7.71 per share on June 25, 2025, Altimmune's stock price fell to $3.61 per share on June 26, 2025, a decline of 53.2% in the span of just a single day.

DEADLINE: October 6, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form-2/?id=170616&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ALT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is October 6, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm

15 West 38th Street, 12th floor

New York, NY, 10018

Email: dg@securitiesclasslaw.com

Phone: (646) 453-8903

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-announces-the-filing-of-a-securities-class-action-on-behalf-of-altimmune-incalt-shareholders-302575196.html

SOURCE Levi & Korsinsky, LLP